The financing round was carried out through a crowdfunding campaign that attracted the investment of a total of 36 investors.
The objective of the capital increase is to adapt the in vitro diagnostic kit-Immunobiogram® for the personalization of the treatment in patients with Rheumatoid Arthritis.
Biohope, a Spanish biotechnology company focused on the development of diagnostic solutions for the personalization of treatments in inflammation diseases, have recently and successfully raised 332,808 euros
A total of 36 investors participated in the crowdfunding campaign, among which are the investment company specialized in biotechnology Bifrost and the executive Ricardo Brage, who acted as lead investors.
The financing round will allow the adaptation of the in vitro diagnostic kit, Immunobiogram®, validated in clinical trials with kidney transplanted patients, for use in the personalization of the treatment of patients with Rheumatoid Arthritis.
The research and development work to adapt the kit will begin in January 2018, and the technical validation of the kit in rheumatoid arthritis patients’ samples is expected in the first quarter of 2020, with the participation of several European hospitals.